Literature DB >> 26149978

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.

Àlex Rovira1, Mike P Wattjes2, Mar Tintoré3, Carmen Tur3, Tarek A Yousry4, Maria P Sormani5, Nicola De Stefano6, Massimo Filippi7, Cristina Auger1, Maria A Rocca7, Frederik Barkhof2, Franz Fazekas8, Ludwig Kappos9, Chris Polman2, David Miller10, Xavier Montalban1.   

Abstract

The clinical use of MRI in patients with multiple sclerosis (MS) has advanced markedly over the past few years. Technical improvements and continuously emerging data from clinical trials and observational studies have contributed to the enhanced performance of this tool for achieving a prompt diagnosis in patients with MS. The aim of this article is to provide guidelines for the implementation of MRI of the brain and spinal cord in the diagnosis of patients who are suspected of having MS. These guidelines are based on an extensive review of the recent literature, as well as on the personal experience of the members of the MAGNIMS (Magnetic Resonance Imaging in MS) network. We address the indications, timing, coverage, reporting and interpretation of MRI studies in patients with suspected MS. Our recommendations are intended to help radiologists and neurologists standardize and optimize the use of MRI in clinical practice for the diagnosis of MS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26149978     DOI: 10.1038/nrneurol.2015.106

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  132 in total

1.  Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis.

Authors:  M Filippi; T Yousry; M A Rocca; G Fesl; R Voltz; G Comi
Journal:  Acta Neurol Scand       Date:  1997-06       Impact factor: 3.209

2.  Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome.

Authors:  D T Okuda; E M Mowry; B A C Cree; E C Crabtree; D S Goodin; E Waubant; D Pelletier
Journal:  Neurology       Date:  2011-01-26       Impact factor: 9.910

3.  A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis.

Authors:  Wei Bian; Kristin Harter; Kathryn E Hammond-Rosenbluth; Janine M Lupo; Duan Xu; Douglas Ac Kelley; Daniel B Vigneron; Sarah J Nelson; Daniel Pelletier
Journal:  Mult Scler       Date:  2012-05-28       Impact factor: 6.312

4.  Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.

Authors:  X Montalban; J Sastre-Garriga; M Filippi; Z Khaleeli; N Téllez; M M Vellinga; C Tur; B Brochet; F Barkhof; M Rovaris; D H Miller; C H Polman; A Rovira; A J Thompson
Journal:  Mult Scler       Date:  2009-12-07       Impact factor: 6.312

5.  Acute demyelinating lesions with restricted diffusion in multiple sclerosis.

Authors:  Konstantin E Balashov; Eric Lindzen
Journal:  Mult Scler       Date:  2012-04-20       Impact factor: 6.312

6.  Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis.

Authors:  Mike P Wattjes; Michael Harzheim; Götz G Lutterbey; Manuela Bogdanow; Stephan Schmidt; Hans H Schild; Frank Träber
Journal:  Neuroradiology       Date:  2007-11-03       Impact factor: 2.804

7.  2010 McDonald criteria for diagnosing pediatric multiple sclerosis.

Authors:  Yair Sadaka; Leonard H Verhey; Manohar M Shroff; Helen M Branson; Douglas L Arnold; Sridar Narayanan; John G Sled; Amit Bar-Or; A Dessa Sadovnick; Melissa McGowan; Ruth Ann Marrie; Brenda Banwell
Journal:  Ann Neurol       Date:  2012-08       Impact factor: 10.422

8.  Phase white matter signal abnormalities in patients with clinically isolated syndrome and other neurologic disorders.

Authors:  J Hagemeier; M Heininen-Brown; T Gabelic; T Guttuso; N Silvestri; D Lichter; L E Fugoso; N Bergsland; E Carl; J J G Geurts; B Weinstock-Guttman; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2014-05-29       Impact factor: 3.825

9.  Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination.

Authors:  J C J Bot; F Barkhof; C H Polman; G J Lycklama à Nijeholt; V de Groot; E Bergers; H J Ader; J A Castelijns
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

10.  Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR.

Authors:  Wolter L de Graaf; Jaco J M Zwanenburg; Fredy Visser; Mike P Wattjes; Petra J W Pouwels; Jeroen J G Geurts; Chris H Polman; Frederik Barkhof; Peter R Luijten; Jonas A Castelijns
Journal:  Eur Radiol       Date:  2011-08-27       Impact factor: 5.315

View more
  113 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  Nonconventional MRI and microstructural cerebral changes in multiple sclerosis.

Authors:  Christian Enzinger; Frederik Barkhof; Olga Ciccarelli; Massimo Filippi; Ludwig Kappos; Maria A Rocca; Stefan Ropele; Àlex Rovira; Torben Schneider; Nicola de Stefano; Hugo Vrenken; Claudia Wheeler-Kingshott; Jens Wuerfel; Franz Fazekas
Journal:  Nat Rev Neurol       Date:  2015-11-03       Impact factor: 42.937

Review 3.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

4.  Association Between Brain Gene Expression, DNA Methylation, and Alteration of Ex Vivo Magnetic Resonance Imaging Transverse Relaxation in Late-Life Cognitive Decline.

Authors:  Lei Yu; Robert J Dawe; Patricia A Boyle; Chris Gaiteri; Jingyun Yang; Aron S Buchman; Julie A Schneider; Konstantinos Arfanakis; Philip L De Jager; David A Bennett
Journal:  JAMA Neurol       Date:  2017-12-01       Impact factor: 18.302

5.  Improving Detection of Multiple Sclerosis Lesions in the Posterior Fossa Using an Optimized 3D-FLAIR Sequence at 3T.

Authors:  A Lecler; I El Sanharawi; J El Methni; O Gout; P Koskas; J Savatovsky
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-27       Impact factor: 3.825

6.  [Inflammatory diseases of the central nervous system].

Authors:  Armin Bachhuber
Journal:  Radiologe       Date:  2021-06-08       Impact factor: 0.635

Review 7.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

Review 8.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

Review 9.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

10.  Optimizing 3D FLAIR to detect MS lesions: pushing past factory settings for precise results.

Authors:  Augustin Lecler; C Bouzad; R Deschamps; F Maizeroi; J C Sadik; A Gueguen; O Gout; H Picard; J Savatovsky
Journal:  J Neurol       Date:  2019-08-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.